Logo image of XRTX.CA

XORTX THERAPEUTICS INC (XRTX.CA) Stock Fundamental Analysis

Canada - TSX-V:XRTX - CA98420Q3061 - Common Stock

1.22 CAD
-0.03 (-2.4%)
Last: 10/14/2025, 7:00:00 PM
Fundamental Rating

1

XRTX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 32 industry peers in the Pharmaceuticals industry. The financial health of XRTX is average, but there are quite some concerns on its profitability. XRTX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year XRTX has reported negative net income.
XRTX had a negative operating cash flow in the past year.
XRTX had negative earnings in each of the past 5 years.
In the past 5 years XRTX always reported negative operating cash flow.
XRTX.CA Yearly Net Income VS EBIT VS OCF VS FCFXRTX.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of XRTX (-68.60%) is worse than 81.25% of its industry peers.
With a Return On Equity value of -92.63%, XRTX is not doing good in the industry: 68.75% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -68.6%
ROE -92.63%
ROIC N/A
ROA(3y)-60.92%
ROA(5y)-49.27%
ROE(3y)-85.37%
ROE(5y)-73.65%
ROIC(3y)N/A
ROIC(5y)N/A
XRTX.CA Yearly ROA, ROE, ROICXRTX.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

XRTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XRTX.CA Yearly Profit, Operating, Gross MarginsXRTX.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for XRTX has been increased compared to 1 year ago.
Compared to 5 years ago, XRTX has less shares outstanding
Compared to 1 year ago, XRTX has a worse debt to assets ratio.
XRTX.CA Yearly Shares OutstandingXRTX.CA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
XRTX.CA Yearly Total Debt VS Total AssetsXRTX.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -8.63, we must say that XRTX is in the distress zone and has some risk of bankruptcy.
XRTX's Altman-Z score of -8.63 is on the low side compared to the rest of the industry. XRTX is outperformed by 78.13% of its industry peers.
There is no outstanding debt for XRTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.63
ROIC/WACCN/A
WACCN/A
XRTX.CA Yearly LT Debt VS Equity VS FCFXRTX.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

A Current Ratio of 1.78 indicates that XRTX should not have too much problems paying its short term obligations.
With a Current ratio value of 1.78, XRTX perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
A Quick Ratio of 1.78 indicates that XRTX should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.78, XRTX is in the better half of the industry, outperforming 71.88% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.78
Quick Ratio 1.78
XRTX.CA Yearly Current Assets VS Current LiabilitesXRTX.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M

More info and screens

0

3. Growth

3.1 Past

XRTX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.07%.
EPS 1Y (TTM)-8.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-423.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-11.64%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XRTX.CA Yearly EPS VS EstimatesXRTX.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XRTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year XRTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XRTX.CA Price Earnings VS Forward Price EarningsXRTX.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XRTX.CA Per share dataXRTX.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

XRTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XORTX THERAPEUTICS INC

TSX-V:XRTX (10/14/2025, 7:00:00 PM)

1.22

-0.03 (-2.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12
Earnings (Next)11-12 2025-11-12
Inst Owners1.23%
Inst Owner ChangeN/A
Ins Owners2.63%
Ins Owner ChangeN/A
Market Cap6.36M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.23
P/tB 2.46
EV/EBITDA N/A
EPS(TTM)-0.76
EYN/A
EPS(NY)-2.18
Fwd EYN/A
FCF(TTM)-0.84
FCFYN/A
OCF(TTM)-0.83
OCFYN/A
SpS0
BVpS0.55
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -68.6%
ROE -92.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-60.92%
ROA(5y)-49.27%
ROE(3y)-85.37%
ROE(5y)-73.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 49.57%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.78
Quick Ratio 1.78
Altman-Z -8.63
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)48.3%
Cap/Depr(5y)87.61%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-423.38%
EPS Next Y-11.64%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y31.68%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-29.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y58.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.89%
OCF growth 3YN/A
OCF growth 5YN/A